Thank you for donating!
You can donate using the following services.
Donate Today
Search
Need support today?
Email: info@npuk.org
Helpline: 0191 415 0693
Main menu
Niemann-Pick Disease
About Us
Care & Support
Research
Fundraising
Resources
Blog
News
NPUK Shop
COVID-19
News
NPUK
>
News
20.05.22
CHMP recommends approval of Xenpozyme® (olipudase alfa), the first and only treatment for ASMD
Read more
17.05.22
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
Read more
27.04.22
NPUK Care & Support Services Survey
Read more
20.04.22
Quality of life experience in patients with Niemann-Pick disease Type C during the COVID-19 pandemic research study
Read more
28.03.22
Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency
Read more
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next
Clinical Trials
CTD Holdings Inc
IntraBio
News
NPUK Annual Family Conference
NPUK News
Orphazyme
Sanofi Genzyme
The Quinn Madeline Foundation
Uncategorized
Vtesse
Donate today
Follow NPUK
Contact us
Donate today
Email: info@npuk.org
Helpline: 0191 415 0693